𝔖 Bobbio Scriptorium
✦   LIBER   ✦

2.281 High risk factors for valvular heart disease from dopamine agonists in Parkinson's disease

✍ Scribed by T. Oeda; M. Masaki; K. Yamamoto; E. Mizuta; S. Kuno; H. Sawada

Book ID
117752933
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
53 KB
Volume
13
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Valvular heart disease in Parkinson's di
Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
✍ Ji-Youn Kim; Eun Joo Chung; Seung Woo Park; Won Yong Lee πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 105 KB

Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors

Valvular heart disease in Parkinson's di
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study
✍ Susann Junghanns; Joerg T. Fuhrmann; Gregor Simonis; Christian Oelwein; Rainer K πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 69 KB

## Abstract Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non‐ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinir